216 related articles for article (PubMed ID: 22792300)
21. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
Kholmanskikh O; Loriot A; Brasseur F; De Plaen E; De Smet C
Int J Cancer; 2008 Feb; 122(4):777-84. PubMed ID: 17957795
[TBL] [Abstract][Full Text] [Related]
22. Suprabasin: Role in human cancers and other diseases.
Tan H; Wang L; Liu Z
Mol Biol Rep; 2022 Feb; 49(2):1453-1461. PubMed ID: 34775572
[TBL] [Abstract][Full Text] [Related]
23. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
Link PA; Zhang W; Odunsi K; Karpf AR
Cancer Immun; 2013; 13():6. PubMed ID: 23390377
[TBL] [Abstract][Full Text] [Related]
24. Suprabasin-A Review.
Pribyl M; Hodny Z; Kubikova I
Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33477529
[TBL] [Abstract][Full Text] [Related]
25. Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.
Rivero-Hinojosa S; Kang S; Lobanenkov VV; Zentner GE
Sci Rep; 2017 Feb; 7():41279. PubMed ID: 28145452
[TBL] [Abstract][Full Text] [Related]
26. [Epigenetic modifications in lung cancer].
Brambilla E
Ann Pathol; 2009 Nov; 29 Spec No 1():S31-3. PubMed ID: 19887246
[No Abstract] [Full Text] [Related]
27. Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter.
Kosaka-Suzuki N; Suzuki T; Pugacheva EM; Vostrov AA; Morse HC; Loukinov D; Lobanenkov V
J Biol Chem; 2011 Aug; 286(31):27378-88. PubMed ID: 21659515
[TBL] [Abstract][Full Text] [Related]
28. BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression.
Nguyen P; Bar-Sela G; Sun L; Bisht KS; Cui H; Kohn E; Feinberg AP; Gius D
Mol Cell Biol; 2008 Nov; 28(21):6720-9. PubMed ID: 18765639
[TBL] [Abstract][Full Text] [Related]
29. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
30. CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer.
Fiorentino FP; Macaluso M; Miranda F; Montanari M; Russo A; Bagella L; Giordano A
Mol Cancer Res; 2011 Feb; 9(2):225-33. PubMed ID: 21325284
[TBL] [Abstract][Full Text] [Related]
31. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.
Horibe R; Hirohashi Y; Asano T; Mariya T; Suzuki T; Takaya A; Saijo H; Shionoya Y; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Watanabe K; Atsuyama E; Toji S; Hirano H; Hasegawa T; Takahashi H; Sato N; Torigoe T
PLoS One; 2017; 12(3):e0171460. PubMed ID: 28248963
[TBL] [Abstract][Full Text] [Related]
32. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract][Full Text] [Related]
33. Discovering a binary CTCF code with a little help from BORIS.
Lobanenkov VV; Zentner GE
Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515
[TBL] [Abstract][Full Text] [Related]
34. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
[TBL] [Abstract][Full Text] [Related]
35. Decreased expression of suprabasin induces aberrant differentiation and apoptosis of epidermal keratinocytes: Possible role for atopic dermatitis.
Aoshima M; Phadungsaksawasdi P; Nakazawa S; Iwasaki M; Sakabe JI; Umayahara T; Yatagai T; Ikeya S; Shimauchi T; Tokura Y
J Dermatol Sci; 2019 Sep; 95(3):107-112. PubMed ID: 31399284
[TBL] [Abstract][Full Text] [Related]
36. Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression.
Kang JY; Song SH; Yun J; Jeon MS; Kim HP; Han SW; Kim TY
Oncogene; 2015 Nov; 34(45):5677-84. PubMed ID: 25703332
[TBL] [Abstract][Full Text] [Related]
37. Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Gray SG; Al-Sarraf N; Baird AM; Cathcart MC; McGovern E; O'Byrne KJ
Eur J Cancer; 2009 Nov; 45(17):3087-97. PubMed ID: 19818596
[TBL] [Abstract][Full Text] [Related]
38. Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes.
Pribyl M; Hubackova S; Moudra A; Vancurova M; Polackova H; Stopka T; Jonasova A; Bokorova R; Fuchs O; Stritesky J; Salovska B; Bartek J; Hodny Z
Mol Oncol; 2020 Oct; 14(10):2403-2419. PubMed ID: 32696549
[TBL] [Abstract][Full Text] [Related]
39. A cell cycle role for the epigenetic factor CTCF-L/BORIS.
Rosa-Garrido M; Ceballos L; Alonso-Lecue P; Abraira C; Delgado MD; Gandarillas A
PLoS One; 2012; 7(6):e39371. PubMed ID: 22724006
[TBL] [Abstract][Full Text] [Related]
40. Expression of the epigenetic factor BORIS (CTCFL) in the human genome.
de Necochea-Campion R; Ghochikyan A; Josephs SF; Zacharias S; Woods E; Karimi-Busheri F; Alexandrescu DT; Chen CS; Agadjanyan MG; Carrier E
J Transl Med; 2011 Dec; 9():213. PubMed ID: 22168535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
